NCT04874597View on ClinicalTrials.gov

Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MS

Active, not recruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

April 10, 2025

Study Completion Date

April 15, 2025

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab

Ocrelizumab treatment will be administered in accordance with the product characteristics approved in Turkey.

Trial Locations (1)

34668

Health Sciences University Istanbul Haydarpaşa Numune Training and Research Hospital, Neurology Department, Istanbul

All Listed Sponsors
collaborator

Haydarpasa Numune Training and Research Hospital

OTHER

lead

Dr Recai Turkoglu

OTHER